» Articles » PMID: 14514651

KIR in Type 1 Diabetes: Disparate Distribution of Activating and Inhibitory Natural Killer Cell Receptors in Patients Versus HLA-matched Control Subjects

Overview
Journal Diabetes
Specialty Endocrinology
Date 2003 Sep 30
PMID 14514651
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Killer cell immunoglobulin-like receptors (KIRs) modulate natural killer cell and T-cell function by interacting with HLA class 1 ligands on target cells. Both KIR and HLA are highly polymorphic. We studied the influence of KIR and HLA class 1 genes on the susceptibility to develop type 1 diabetes. The results showed increased numbers of activating KIR genes in patients compared with control subjects (P = 0.049). The combination of the activating KIR2DS2 gene, together with its putative HLA ligand, was present more frequently in patients than in diabetes high-risk HLA-matched control subjects (P = 0.030). Moreover, our results imply that an increase in activating KIR2DS2-HLA ligand pairs combined with a lack of inhibitory KIR-HLA ligand pairs is associated with an additional risk to develop type 1 diabetes in individuals with diabetes high-risk HLA alleles (P = 0.035). We propose that the genetic imbalance between KIR and their HLA class 1 ligands may enhance the activation of T-cells with a low affinity for pancreatic self-antigens, thereby contributing to the pathogenesis of type 1 diabetes.

Citing Articles

Inhibitory KIRs decrease HLA class II-mediated protection in Type 1 Diabetes.

Mora-Bitria L, Debebe B, Miners K, Ladell K, Kaur C, Traherne J PLoS Genet. 2024; 20(12):e1011456.

PMID: 39724143 PMC: 11741628. DOI: 10.1371/journal.pgen.1011456.


Fifty years of HLA-associated type 1 diabetes risk: history, current knowledge, and future directions.

Noble J Front Immunol. 2024; 15:1457213.

PMID: 39328411 PMC: 11424550. DOI: 10.3389/fimmu.2024.1457213.


Decoding the diversity of killer immunoglobulin-like receptors by deep sequencing and a high-resolution imputation method.

Sakaue S, Hosomichi K, Hirata J, Nakaoka H, Yamazaki K, Yawata M Cell Genom. 2023; 2(3):100101.

PMID: 36777335 PMC: 9903714. DOI: 10.1016/j.xgen.2022.100101.


Killer-Cell Immunoglobulin-like Receptor Diversity in an Admixed South American Population.

Castrillon M, Marin N, Karduss-Urueta A, Velasquez S, Alvarez C Cells. 2022; 11(18).

PMID: 36139351 PMC: 9496851. DOI: 10.3390/cells11182776.


Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health.

Pollock N, Harrison G, Norman P J Allergy Clin Immunol Pract. 2022; 10(7):1763-1775.

PMID: 35561968 PMC: 10038757. DOI: 10.1016/j.jaip.2022.04.036.